Background Statins reduce adverse cardiovascular outcomes and slow the progression of
coronary atherosclerosis in proportion to their ability to reduce low-density lipoprotein (LDL) …

ContextPrior intravascular ultrasound (IVUS) trials have demonstrated slowing or halting of
atherosclerosis progression with statin therapy but have not shown convincing evidence of …

ContextStatin drugs reduce both atherogenic lipoproteins and cardiovascular morbidity and
mortality. However, the optimal strategy and target level for lipid reduction remain uncertain …

High-dose rosuvastatin induces regression of coronary atherosclerosis, but it remains
uncertain whether usual-dose statin has similar effects. We compared the effects of …

Background Recent trials have demonstrated better outcomes with intensive than with
moderate statin treatment. Intensive treatment produced greater reductions in both low …

ContextStatins reduce low-density lipoprotein cholesterol (LDL-C) levels and slow
progression of coronary atherosclerosis. However, no data exist describing the relationship …

Statins reduce both atherogenic lipoproteins and high-sensitivity C-reactive protein
(hsCRP). The optimal strategy for administration of lipid-lowering agents has evolved …

Aims The impact of baseline coronary plaque burden on the clinical outcome in patients
receiving aggressive low-density lipoprotein cholesterol (LDL-C) lowering therapy to levels< …

Statins are the most commonly prescribed agents for lowering levels of low-density
lipoprotein (LDL) cholesterol. Although dose-dependent reductions in levels of atherogenic …

Aims Statins can inhibit the progression of coronary atherosclerosis. We aimed to
characterize clinical factors that associate with differing measures of coronary atheroma …